The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2022 Aug 10

PMID 35947993

Authors

Tetsuji Terazawa

Takeshi Kato

Masahiro Goto

Katsuya Ohta

Hironaga Satake

Shingo Noura

Yoshinori Kagawa

Hisato Kawakami

Hiroko Hasegawa

Kazuhiro Yanagihara

Tatsushi Shingai

Ken Nakata

Masahito Kotaka

Masayuki Hiraki

Ken Konishi

Shiro Nakae

Daisuke Sakai

Yukinori Kurokawa

Toshio Shimokawa

Toshimasa Tsujinaka

Taroh Satoh

Affiliations

Soon will be listed here.

Abstract

Background: We previously reported the response rate of a phase II OGSG1602 study on panitumumab in chemotherapy-naive frail or elderly patients with RAS wild-type unresectable colorectal cancer (CRC) [Terazawa T, Kato T, Goto M, et al. Oncologist. 2021;26(1):17]. Herein, we report a survival analysis.

Methods: Patients aged ≥65 years and considered unsuitable for intensive chemotherapy or aged ≥76 years were enrolled. Primary tumors located from the cecum to the transverse colon were considered right-sided tumors (RSTs); those located from the splenic flexure to the rectum were considered left-sided tumors (LSTs).

Results: Among the 36 enrolled patients, 34 were included in the efficacy analysis, with 26 and 8 having LSTs and RSTs, respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.0 [95% CI, 5.4-10.0] and 17.5 months (95% CI, 13.8-24.3), respectively. Although no significant differences existed in PFS between patients with LST and RST {6.6 (95% CI, 5.4-11.5) vs. 4.9 months [95% CI, 1.9-not available (NA), P = .120]}, there were significant differences in OS [19.3 (95% CI, 14.2-NA) vs.12.3 months (95% CI, 9.9-NA), P = .043].

Conclusion: Panitumumab showed favorable OS in frail or elderly patients with RAS wild-type CRC and no prior exposure to chemotherapy. Panitumumab may be optimal for patients with LSTs (UMIN Clinical Trials Registry Number UMIN000024528).

Citing Articles

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer.

Rosati G, Montrone M, Pacilio C, Colombo A, Cicero G, Paragliola F J Clin Med. 2022; 11(23).

PMID: 36498683 PMC: 9739901. DOI: 10.3390/jcm11237108.

References

Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin D . Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14(11):1077-1085. DOI: 10.1016/S1470-2045(13)70154-2. View

Sastre J, Massuti B, Pulido G, Guillen-Ponce C, Benavides M, Manzano J . First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer. 2015; 51(11):1371-80. DOI: 10.1016/j.ejca.2015.04.013. View

Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H . S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol. 2018; 29(3):624-631. PMC: 5889030. DOI: 10.1093/annonc/mdx816. View

Perkins N, Schisterman E . The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006; 163(7):670-5. PMC: 1444894. DOI: 10.1093/aje/kwj063. View

van Leersum N, Janssen-Heijnen M, Wouters M, Rutten H, Coebergh J, Tollenaar R . Increasing prevalence of comorbidity in patients with colorectal cancer in the South of the Netherlands 1995-2010. Int J Cancer. 2012; 132(9):2157-63. DOI: 10.1002/ijc.27871. View

Soldevilla B, Carretero-Puche C, Gomez-Lopez G, Al-Shahrour F, Riesco M, Gil-Calderon B . The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. Eur J Cancer. 2019; 123:118-129. DOI: 10.1016/j.ejca.2019.09.008. View

Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View

Ikoma T, Shimokawa M, Kotaka M, Matsumoto T, Nagai H, Boku S . Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. BMC Cancer. 2021; 21(1):518. PMC: 8105976. DOI: 10.1186/s12885-021-08271-z. View

Aarts M, Lemmens V, Louwman M, Kunst A, Coebergh J . Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome. Eur J Cancer. 2010; 46(15):2681-95. DOI: 10.1016/j.ejca.2010.04.026. View

10.

Seymour M, Thompson L, Wasan H, Middleton G, Brewster A, Shepherd S . Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011; 377(9779):1749-59. PMC: 3109515. DOI: 10.1016/S0140-6736(11)60399-1. View

11.

Brule S, Jonker D, Karapetis C, OCallaghan C, Moore M, Wong R . Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015; 51(11):1405-14. DOI: 10.1016/j.ejca.2015.03.015. View

12.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu R . Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2017; 29(1):44-70. DOI: 10.1093/annonc/mdx738. View

13.

Bekaii-Saab T . Moving forward with expanding to an "all-RAS mutational analysis" in metastatic colorectal cancer: beyond KRAS mutations. J Natl Compr Canc Netw. 2014; 12(2):299-300. DOI: 10.6004/jnccn.2014.0027. View

14.

Heinemann V, Stintzing S, Modest D, Giessen-Jung C, Michl M, Mansmann U . Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer. 2015; 51(14):1927-36. DOI: 10.1016/j.ejca.2015.06.116. View

15.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

16.

Missiaglia E, Jacobs B, DArio G, Di Narzo A, Soneson C, Budinska E . Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014; 25(10):1995-2001. DOI: 10.1093/annonc/mdu275. View

17.

Terazawa T, Kato T, Goto M, Ohta K, Noura S, Satake H . Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602. Oncologist. 2020; 26(1):17-e47. PMC: 7794186. DOI: 10.1002/ONCO.13523. View

18.

Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L . Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol. 2015; 26(6):1188-1194. DOI: 10.1093/annonc/mdv112. View

19.

Schwartzberg L, Rivera F, Karthaus M, Fasola G, Canon J, Hecht J . PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic.... J Clin Oncol. 2014; 32(21):2240-7. DOI: 10.1200/JCO.2013.53.2473. View

20.

Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A . Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. Oncologist. 2015; 20(11):1261-5. PMC: 4718427. DOI: 10.1634/theoncologist.2015-0171. View